All News

The CELESTIAL-301 trial evaluating SynKIR-310, a novel chimeric antigen receptor T-cell therapy, has dosed its first patient with relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL).

In part 2 of our interview with Katie Abouzahr, MD, Johnson & Johnson Innovative Medicine, we discuss the challenge inherent in treating adolescents who have the myasthenia gravis and how nipocalimab works via FcRn blockade to reduce the circulating autoantibodies that drive myasthenia gravis.

Sen. Bill Cassidy, MD, (R, Louisiana) holds a key vote on Robert F. Kennedy Jr's HHS Secretary confirmation. When Cassidy asked for a strategy on Medicare and Medicaid, Kennedy could not provide one.

Although long-term nursing home stay or death decreased before the COVID-19 pandemic, the trend slowed during the pandemic across all racial and ethnic groups.

Patients with myelodysplastic syndromes (MDS) who undergo allogeneic hematopoietic stem cell transplantation (allo-HSCT) are older and face worse outcomes compared with non-MDS patients, according to posters presented at the 2024 American Society of Hematology meeting.

The design of the Enhancing Oncology Model (EOM) was a perfect fit for Minnesota Oncology.

Extranodal non-Hodgkin lymphoma (NHL) makes up over one-third of NHL cases, yet remains understudied and in need of deeper research considerations.

According to a review of hospital-based cross-sectional studies, almost half the type 2 diabetes population is micronutrient deficient.

The latest semaglutide (Ozempic; Novo Nordisk) approval is set to tackle a major need for patients with both type 2 diabetes (T2D) and chronic kidney disease (CKD), addressing their cardiovascular (CV) and kidney disease risks.

First-line maintenance (1LM) niraparib significantly extends progression-free survival (rwPFS) and time to next treatment (rwTTNT) in patients with epithelial ovarian cancer (EOC), with the greatest benefit observed in those considered homologous recombination-deficient (HRd) and those with BRCA-mutated (BRCAm) tumors.

According to the CDC, frequent consumption of sugary drinks is linked to adverse health outcomes that include obesity, type 2 diabetes, heart disease, nonalcoholic liver disease, and gout.

The pause has raised concerns among health officials and state leaders, as the vague wording leaves billions in Medicaid funding at risk, potentially disrupting coverage for millions of Americans.

Eleven drugs are poised to reach blockbuster status, dramatically improving patient outcomes on a global scale.

Patients with hidradenitis suppurativa experience knowledge gaps on effective treatments and addressing these gaps could help prevent tissue damage among these patients.

The investigators believe their decades-spanning analysis underscores the need to address access barriers to anti-obesity therapeutics.

Michael Ashley Stein, PhD, JD, speaks about how disabled individuals are at a disadvantage when it comes to preparing for natural disasters, specifically during wildfires.

Prolonged immigration detention is significantly associated with worsened self-rated health, along with high rates of posttraumatic stress disorder (PTSD) and mental illness.

Newer treatments target pathways like Delta-like ligand 3, poly-ADP-ribose polymerase, and histone deacetylase to address small cell lung cancer's aggressive nature and resistance to conventional therapy.

The approval is based on findings from a phase 3 study which demonstrated the drug’s superiority over chemotherapy.

Although most of the innovation in treatment has come in the past decade, new treatments for glaucoma are still being tested, albeit at a slower pace.

Sarah Anderson, oncology strategy lead director, Novotech, discusses the growing prominence of triple-negative breast cancer clinical trials in the Asia-Pacific region, and the significant investments being made with novel biomarkers.

Young patients with cancer residing in historically redlined areas face a significantly higher risk of mortality, demonstrating that structural racism contributes to disparities in survival outcomes.

In patients with HIV, alcohol reduction after a 6-month intervention and adherence to isoniazid had no effect on the high levels of viral suppression reported at baseline.

Amazon Pharmacy's RxPass program shows promise in boosting medication adherence and reducing costs, according to a study.

Biosimilar SB17 demonstrated clinical biosimilarity to reference ustekinumab after switching among patients with psoriasis for up to 52 weeks.

The FDA approves a new maintenance dosing regimen for lecanemab (Leqembi; Eisai) in patients with early-stage Alzheimer disease (AD), enabling a transition from biweekly to once-every-4-week dosing while preserving clinical and biomarker benefits.

Serum soluble interleukin-2 receptor (sIL-2R) levels have been a great diagnostic tool for non-Hodgkin lymphoma (NHL) and could provide further benefits for distinguishing soft-tissue NHL from other soft tissue tumors.

Patients with metabolic dysfunction-associated steotohepatitis (MASH) who are already taking a glucagon-like peptide-1 receptor agonist (GLP-1RA) could see their liver health improve with the addition of efruxifermin.

An ustekinumab biosimilar to Stelara launched in France, completing its rollout across 5 major European markets and paving the way for its US launch.

Highlights from last week include President Trump's executive orders, the FDA approval of esketamine nasal spray for depression, mental health access through Medicaid Managed Care, the impact of travel time on surgical outcomes, and life expectancy disparities.